FDA expands approved use of metastatic breast cancer treatment to include male patients

The FDA is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.
Source: Food and Drug Administration - Category: American Health Source Type: news

Related Links:

More News: American Health | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Food and Drug Administration (FDA) | HER2 | Hormones